Celldex Therapeutics Inc. (CLDX) Stock Rating Reaffirmed by Wedbush
Celldex Therapeutics Inc. (NASDAQ:CLDX)‘s stock had its “neutral” rating reiterated by equities research analysts at Wedbush in a report issued on Tuesday. They currently have a $3.00 price objective on the biopharmaceutical company’s stock. Wedbush’s price objective points to a potential downside of 25.56% from the stock’s previous close.
CLDX has been the subject of several other reports. Roth Capital set a $7.00 price objective on Celldex Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, November 2nd. Brean Capital started coverage on Celldex Therapeutics in a research note on Tuesday, October 4th. They issued a “buy” rating and a $16.00 price objective for the company. Zacks Investment Research cut Celldex Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 19th. Cantor Fitzgerald reiterated a “buy” rating and set a $9.00 price target on shares of Celldex Therapeutics in a research report on Monday, October 10th. Finally, Aegis started coverage on Celldex Therapeutics in a research report on Monday. They set a “buy” rating for the company. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $7.75.
Celldex Therapeutics (NASDAQ:CLDX) opened at 4.03 on Tuesday. The company’s market capitalization is $405.20 million. The firm has a 50-day moving average of $3.63 and a 200-day moving average of $4.04. Celldex Therapeutics has a 52 week low of $2.85 and a 52 week high of $18.62.
Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04. The business had revenue of $2.20 million for the quarter, compared to analysts’ expectations of $1.09 million. Celldex Therapeutics had a negative net margin of 1,923.41% and a negative return on equity of 49.27%. The firm’s revenue for the quarter was up 115.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.32) earnings per share. Equities analysts expect that Celldex Therapeutics will post ($1.34) earnings per share for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in CLDX. Marcus Capital LLC raised its position in Celldex Therapeutics by 0.5% in the third quarter. Marcus Capital LLC now owns 112,200 shares of the biopharmaceutical company’s stock worth $453,000 after buying an additional 600 shares during the period. Teachers Advisors LLC raised its position in shares of Celldex Therapeutics by 0.7% in the third quarter. Teachers Advisors LLC now owns 166,149 shares of the biopharmaceutical company’s stock valued at $671,000 after buying an additional 1,207 shares during the period. Zacks Investment Management raised its position in shares of Celldex Therapeutics by 2.3% in the second quarter. Zacks Investment Management now owns 68,681 shares of the biopharmaceutical company’s stock valued at $302,000 after buying an additional 1,517 shares during the period. National Planning Corp raised its position in shares of Celldex Therapeutics by 3.1% in the second quarter. National Planning Corp now owns 55,246 shares of the biopharmaceutical company’s stock valued at $251,000 after buying an additional 1,650 shares during the period. Finally, BlackRock Group LTD raised its position in shares of Celldex Therapeutics by 2.6% in the third quarter. BlackRock Group LTD now owns 70,520 shares of the biopharmaceutical company’s stock valued at $286,000 after buying an additional 1,767 shares during the period. 78.41% of the stock is currently owned by institutional investors.
About Celldex Therapeutics
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII).
Receive News & Stock Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related stocks with our FREE daily email newsletter.